<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559972</url>
  </required_header>
  <id_info>
    <org_study_id>SKM18-HULK-INJ</org_study_id>
    <nct_id>NCT03559972</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy and Tolerability of Two Topical Regimens in Subjects With Moderate to Severe Facial Photodamage Who Have Received Cosmetic Injections</brief_title>
  <official_title>Open-Label, Randomized, Multi-center Study to Evaluate the Efficacy and Tolerability of Two Topical Regimens in Subjects With Moderate to Severe Facial Photodamage Who Have Received Cosmetic Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and tolerability of two topical regimens (containing
      cosmetic human fibroblast-derived, physiologically-balanced growth factor combination
      products (HULK and TNS Essential Serum)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2018</start_date>
  <completion_date type="Actual">December 3, 2018</completion_date>
  <primary_completion_date type="Actual">December 3, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Clinical grading of the full face on the Griffith's modified 10-point scale</measure>
    <time_frame>Baseline, Week 4, Week 16</time_frame>
    <description>Investigator will assess the following parameters on a Griffith's modified 10-point scale (0 = None, 1 to 3 = Mild, 4 to 6 = Moderate, 7 to 9 = Severe)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Facial Photodamage</condition>
  <arm_group>
    <arm_group_label>Treatment Group #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject in Treatment group 1 will apply the following products in the morning and evening.
SkinMedica Facial Cleanser
Hulk (cosmetic investigational)
Marvel AM (cosmetic investigational)
Marvel PM (cosmetic investigational)
SkinMedica HA5 Rejuvenating Hydrator
SkinMedica Rejuvenative Moisturizer
SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject in Treatment group 2 will apply the following products in the morning and evening.
SkinMedica Facial Cleanser
SkinMedica TNS Essential Serum
Marvel AM (cosmetic investigational)
Marvel PM (cosmetic investigational)
SkinMedica HA5 Rejuvenating Hydrator
SkinMedica Rejuvenative Moisturizer
SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>on-label facial injection</intervention_name>
    <description>Assessing if adding SkinMedica's cosmetic topical skincare regimens improves the appearance of the skin and the subject's experience, when used after pre-elected on-label facial injection</description>
    <arm_group_label>Treatment Group #1</arm_group_label>
    <arm_group_label>Treatment group #2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects aged 30 years and older with Fitzpatrick skin type I-VI

          -  Pre-elected to receive on-label facial injection(s) (i.e. neuromodulator injection
             and/or filler injections)

          -  Experienced injection patients defined as having received at least 1 facial injection
             in the past 2 years.

          -  Current users of non-physician-dispensed brand skin care products (i.e. only using
             products that are available at drugstores or department stores

          -  Good general health and free of any disease state or physical condition (e.g.
             psoriasis, rosacea, scars, tattoos etc.)

          -  Willingness to have exams and digital photos performed on the face.

          -  Willingness to cooperate and participate by following study requirements (including
             using the provided test products) for the duration of the study and to report any
             adverse event symptoms or reactions immediately.

          -  Willingness to discontinue use of their current skincare products starting at their
             Week 4 visit in this study.

          -  Willingness to not use any other products, including self-tanners, on their face for
             the duration of the study other than make-up with an established tolerance of at least
             1 month.

          -  Willingness to withhold all facial treatments during the course of the study including
             microdermabrasion, peels, facials, laser treatments and tightening treatments.

          -  .Willingness to avoid as much as possible, direct and prolonged sun exposure for the
             duration of the study (including tanning beds), especially from 10 AM to 2 PM.
             Subjects are asked to wear protective clothing prior to and during exposure.

          -  If of child-bearing potential, willing to use an acceptable method of contraception
             throughout the study. Acceptable methods of birth

        Exclusion Criteria:

          -  Who are nursing, pregnant, or planning to become pregnant during the study according
             to subject self-report.

          -  Individuals with active symptoms of allergy, cold sore or warts, active psoriasis or
             eczema, rosacea, sunburn, open wounds, neurotic excoriations, excessive scarring,
             tattoos, or other skin conditions in the test areas that would interfere with the
             assessments of this study.

          -  Uncontrolled disease such as diabetes, hypertension, hyper or hypo-thyroidism, active
             hepatitis, immune deficiency, or autoimmune.

          -  Individuals who have a pre-existing or dormant dermatologic condition (e.g.,
             psoriasis, atopic dermatitis, rosacea, skin cancer, etc.)

          -  Individuals who require electrolysis, waxing, or use depilatories on the face during
             conduct of the study.

          -  Individuals with any planned surgeries and/or invasive medical procedures during the
             course of the study

          -  Individuals who are currently participating in any other facial usage study or have
             participated in any clinical trial within 4 weeks prior to inclusion of the study.

          -  Subjects currently on or planning to participate on any type of research study at
             another facility or a doctor's office during this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Makino</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cosmetic Laser Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce and Associates, PA, The Center for Skin Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com/</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR‚ÄêCTRegistration@Allergan.com for assistance</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

